You are here

Topical Silver Sulfadiazine Formulations with Improved Efficacy and Toxicity Prof

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM109610-01A1
Agency Tracking Number: R43GM109610
Amount: $270,598.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA14-077
Solicitation Year: 2017
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-25
Award End Date (Contract End Date): 2016-09-22
Small Business Information
Spokane, WA 99202-5029
United States
DUNS: 078498897
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (509) 210-0736
Business Contact
Phone: (509) 210-0736
Research Institution

DESCRIPTION provided by applicant Silver Sulfadiazine SSD is the most widely used topical antimicrobial agent in the world and while effective against a wide variety of pathogens i has been shown to delay wound healing Formulation of SSD into creams and gels with the inclusion of a naturally occurring component additive has been shown to significantly lower the toxicity of the formulation improve the solubility of SSD and improve the efficacy of the drug against several leading burn pathogens The major specific aims of the proposed research involve the preparation andamp formulation processing of the SSD in cream and gel formulations with varying concentrations of the naturally occurring additive determination of antimicrobial efficacy cyto compatability and evaluation in an infected burn wound model in the rat The primary objectives of the proposed therapy are resolution of infection improvement of healing and reduction in overall inflammation This innovative and rational approach to an improved topical antimicrobial therapy is founded on the basis of several different studies that have revealed promising bioapplicable attributes of this improved and commonly applied therapy The end goal of this project is to enable the next phase of development of one or more of these novel microbicidal formulations that will be targeted for the treatment of burn wounds PUBLIC HEALTH RELEVANCE Infection is the most common and most serious complication of a major burn injury Despite improvements in burn wound management and antimicrobial therapy technologies sepsis related to the burn accounts for of deaths in burn patients today Other complicating issues that hamper efficient healing include cellular oxidative stress topical agent toxicity and ease of patient treatment Antimicrobial creams and gels using a well known and controversial antimicrobial compound formulated to minimize toxicity so as to not delay healing provide good efficacy against relevant burn pathogens maintain soothing and hydrating properties remain cost effective and easy to clean from the patient is proposed as a solution to the aforementioned complications of burn injury

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government